Embed Size (px)
DESCRIPTION
Can the Specialty Beast Be Tamed?. Steven B. Miller, MD Express Scripts. Specialty Growth Continues to Outpace Traditional Drug Market. 27%. 21%. Source: Express Scripts analysis of IMS data. 2. Specialty Growth Continues to Outpace Traditional Drug Market. 27%. 21%. - PowerPoint PPT Presentation
Citation preview
Can the Specialty Beast Be Tamed?
Steven B. Miller, MDExpress Scripts
2008 Express Scripts, Inc. All Rights Reserved.
2
Specialty Growth Continues to Outpace Traditional Drug Market
Source: Express Scripts analysis of IMS data.
21%
2008 Express Scripts, Inc. All Rights Reserved.
3
Specialty Growth Continues to Outpace Traditional Drug Market
Source: Express Scripts analysis of IMS data.
21%
27%
2008 Express Scripts, Inc. All Rights Reserved.
4
Specialty Growth Continues to Outpace Traditional Drug Market
Source: Express Scripts analysis of IMS data.
21%
27%
2008 Express Scripts, Inc. All Rights Reserved.
5
Agenda
2008 Express Scripts, Inc. All Rights Reserved.
6
What Are Specialty Medications?
2008 Express Scripts, Inc. All Rights Reserved.
77
Overall Specialty Trend: 14%
PMPY
2008 Express Scripts, Inc. All Rights Reserved.
8
“Specialty”: Now the #1 Therapy Class
PMPY
2008 Express Scripts, Inc. All Rights Reserved.
99
Utilization Drove Trend More Than Last Year
PMPY
2008 Express Scripts, Inc. All Rights Reserved.
1010
Key Specialty Therapy Classes2006:2007
PM
PY
+ 17%+ 17%
+ 1%+ 1%
- 10%- 10%
+ 20%+ 20%
+ 16%+ 16%
+ 18%+ 18%
PMPY
+ 6%+ 6%
2008 Express Scripts, Inc. All Rights Reserved.
1111
Key Specialty Therapy Classes2006:2007
PM
PY
PMPY
+ 17%+ 17%
+ 1%+ 1%
- 10%- 10%
+ 20%+ 20%
+ 16%+ 16%
+ 18%+ 18%
+ 6%+ 6%
2008 Express Scripts, Inc. All Rights Reserved.
1212
Expanded and Earlier UseInflammatory Conditions
2008 Express Scripts, Inc. All Rights Reserved.
1313
Expanded and Earlier UseInflammatory Conditions
2008 Express Scripts, Inc. All Rights Reserved.
1414
Price Drove TrendMultiple Sclerosis
2008 Express Scripts, Inc. All Rights Reserved.
1515
Price Drove TrendMultiple Sclerosis
2008 Express Scripts, Inc. All Rights Reserved.
1616
Price Drove TrendMultiple Sclerosis
2008 Express Scripts, Inc. All Rights Reserved.
1717
Price, Place and ProductCancer
2008 Express Scripts, Inc. All Rights Reserved.
1818
Price, Place and ProductCancer
2008 Express Scripts, Inc. All Rights Reserved.
1919
Price, Place and ProductCancer
2008 Express Scripts, Inc. All Rights Reserved.
2020
Safety Changed the Landscape
Blood Cell Deficiency
2008 Express Scripts, Inc. All Rights Reserved.
2121
Safety Changed the Landscape
Blood Cell Deficiency
2008 Express Scripts, Inc. All Rights Reserved.
2222
Prevalence and Price Overwhelmed Mix
Growth Hormone
2008 Express Scripts, Inc. All Rights Reserved.
2323
Prevalence and Price Overwhelmed Mix
Growth Hormone
2008 Express Scripts, Inc. All Rights Reserved.
24
Growth Hormone Use Is Rapidly
Moving Into Older Patients
Users above age 20
2008 Express Scripts, Inc. All Rights Reserved.
2525
Medical Shifted to PharmacyAnticoagulants
2008 Express Scripts, Inc. All Rights Reserved.
2626
Medical Shifted to PharmacyAnticoagulants
2008 Express Scripts, Inc. All Rights Reserved.
2727
Where are the Patients Going?
Hepatitis C
2008 Express Scripts, Inc. All Rights Reserved.
2828
Where are the Patients Going?
Hepatitis C
2008 Express Scripts, Inc. All Rights Reserved.
Hepatitis C Prevention Is Working
US has 3.2 Million Chronically Infected and 10,000 Annual Deaths
29
http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden.pdf accessed March 24, 2008
2008 Express Scripts, Inc. All Rights Reserved.
Hepatitis C Prevention Is Working
US has 3.2 Million Chronically Infected and 10,000 Annual Deaths
30
http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden.pdf accessed March 24, 2008
2008 Express Scripts, Inc. All Rights Reserved.
31
Specialty Growth Continues to Outpace Traditional Drug Market
Source: Express Scripts analysis of IMS data.
21%
27%
2008 Express Scripts, Inc. All Rights Reserved.
32
Follow-on Biologic Savings Opportunity
ESI studied four classes of specialty drugs
2008 Express Scripts, Inc. All Rights Reserved.
33
Follow-on Biologic Savings Opportunity
ESI studied four classes of specialty drugs
2008 Express Scripts, Inc. All Rights Reserved.
34
In the first ten years: $71 Billion Savings
$ B
illio
ns
Inflation and prevalence drive trend in this modelInflation and prevalence drive trend in this model
2008 Express Scripts, Inc. All Rights Reserved.
Every Study Says “Billions”
2008 Express Scripts, Inc. All Rights Reserved.
36
Key Issues
2008 Express Scripts, Inc. All Rights Reserved.
2007 Was An Active Legislative Year for Follow-On
Biologics
High-level excerpts of selected issues; not a complete description of legislative proposals.
2008 Express Scripts, Inc. All Rights Reserved.
2008 Biogenerics Legislation
2008 Express Scripts, Inc. All Rights Reserved.
39
Conclusions
